Georg Voelcker

644 total citations
40 papers, 530 citations indexed

About

Georg Voelcker is a scholar working on Pathology and Forensic Medicine, Public Health, Environmental and Occupational Health and Molecular Biology. According to data from OpenAlex, Georg Voelcker has authored 40 papers receiving a total of 530 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pathology and Forensic Medicine, 9 papers in Public Health, Environmental and Occupational Health and 8 papers in Molecular Biology. Recurrent topics in Georg Voelcker's work include Chemotherapy-induced organ toxicity mitigation (13 papers), Acute Lymphoblastic Leukemia research (9 papers) and Chemical Reactions and Isotopes (7 papers). Georg Voelcker is often cited by papers focused on Chemotherapy-induced organ toxicity mitigation (13 papers), Acute Lymphoblastic Leukemia research (9 papers) and Chemical Reactions and Isotopes (7 papers). Georg Voelcker collaborates with scholars based in Germany and Colombia. Georg Voelcker's co-authors include H. J. Hohorst, G. Peter, Hohorst Hj, Thomas Wagner, T. Wagner, Ulrich Weser, Theodoro Marcel Wagner, Hans‐Jürgen Hartmann, Carl Djerassi and Wolfgang Voelter and has published in prestigious journals such as Cancer, FEBS Letters and Die Naturwissenschaften.

In The Last Decade

Georg Voelcker

39 papers receiving 488 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Georg Voelcker Germany 15 209 162 108 88 84 40 530
Ulf Niemeyer Germany 13 184 0.9× 170 1.0× 64 0.6× 93 1.1× 68 0.8× 43 601
Jörg Pohl Germany 12 236 1.1× 168 1.0× 74 0.7× 190 2.2× 40 0.5× 15 687
G. Peter Germany 13 109 0.5× 148 0.9× 85 0.8× 50 0.6× 52 0.6× 36 465
Larry M. Allen United States 15 98 0.5× 300 1.9× 63 0.6× 233 2.6× 24 0.3× 38 642
Yei Mei Peng United States 18 41 0.2× 386 2.4× 95 0.9× 238 2.7× 47 0.6× 22 968
Eliahu Boger United States 11 53 0.3× 159 1.0× 33 0.3× 62 0.7× 157 1.9× 18 512
M. J. van Maanen Netherlands 10 45 0.2× 117 0.7× 24 0.2× 140 1.6× 22 0.3× 14 358
Bo Jiao China 15 36 0.2× 495 3.1× 95 0.9× 81 0.9× 94 1.1× 56 882
Shinji Hourai Japan 8 168 0.8× 209 1.3× 23 0.2× 43 0.5× 48 0.6× 11 1.1k
Nicolas Albin France 13 209 1.0× 249 1.5× 22 0.2× 305 3.5× 46 0.5× 34 662

Countries citing papers authored by Georg Voelcker

Since Specialization
Citations

This map shows the geographic impact of Georg Voelcker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Georg Voelcker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Georg Voelcker more than expected).

Fields of papers citing papers by Georg Voelcker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Georg Voelcker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Georg Voelcker. The network helps show where Georg Voelcker may publish in the future.

Co-authorship network of co-authors of Georg Voelcker

This figure shows the co-authorship network connecting the top 25 collaborators of Georg Voelcker. A scholar is included among the top collaborators of Georg Voelcker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Georg Voelcker. Georg Voelcker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Voelcker, Georg. (2023). Mechanism-of-Action-Based Development of New Cyclophosphamides. MDPI (MDPI AG). 1(2). 158–171. 1 indexed citations
2.
Voelcker, Georg. (2020). Causes and possibilities to circumvent cyclophosphamide toxicity. Anti-Cancer Drugs. 31(6). 617–622. 16 indexed citations
3.
Voelcker, Georg. (2020). Aldophosphamide-thiazolidine (NSC-613060) an oxazaphosphorine cytostatic that crosses the blood brain barrier. Anti-Cancer Drugs. 32(1). 61–65. 2 indexed citations
4.
5.
Voelcker, Georg. (2019). Oxazaphosphorine cytostatics. Anti-Cancer Drugs. 30(5). 435–440. 3 indexed citations
6.
Voelcker, Georg. (2018). Immunostimulating and cancer-reductive experimental therapy with the oxazaphosphorine cytostatic SUM-IAP. Anti-Cancer Drugs. 29(5). 411–415. 3 indexed citations
7.
Voelcker, Georg. (2017). Influence of the alkylating function of aldo-Ifosfamide on the anti-tumor activity. Anti-Cancer Drugs. 29(1). 75–79. 6 indexed citations
8.
Voelcker, Georg. (2016). Enhancement of antitumor activity of the oxazaphosphorine cytostatic SUM-IAP by N-methylformamide. Journal of Cancer Research and Clinical Oncology. 142(6). 1183–1189. 3 indexed citations
9.
Voelcker, Georg & H. J. Hohorst. (1998). Structure/activity studies with thiazolidinyl- and perhydrothiazinyl-phosphamide ester. Journal of Cancer Research and Clinical Oncology. 124(6). 297–300. 9 indexed citations
10.
Voelcker, Georg, et al.. (1997). Thiazolidinyl- and perhydrothiazinylphosphamidesters: toxicity and preliminary antitumour evaluation. Journal of Cancer Research and Clinical Oncology. 123(11-12). 623–631. 7 indexed citations
11.
Voelcker, Georg, et al.. (1988). Low toxicity cancer chemotherapy by suicide inactivation of DNA polymerase ? holoenzyme: first results with new thiazolidinyl-and perhydrothiazinyl-ethyl-N-mustard-phosphamide esters. Journal of Cancer Research and Clinical Oncology. 114(3). 309–311. 2 indexed citations
12.
Hohorst, H. J., et al.. (1986). The enzymatic basis of cyclophosphamide specificity. Advances in Enzyme Regulation. 25. 99–122. 20 indexed citations
13.
Wagner, T., et al.. (1981). Comparative study on human pharmacokinetics of activated ifosfamide and cyclophosphamide by a modified fluorometric test. Journal of Cancer Research and Clinical Oncology. 100(1). 95–104. 61 indexed citations
14.
Voelcker, Georg, et al.. (1980). �ber Blutspiegel und Urin-Ausscheidung von aktiviertem Cyclophosphamid und seinen Deaktivierungsprodukten beim Menschen. Journal of Cancer Research and Clinical Oncology. 96(1). 79–92. 32 indexed citations
15.
Voelcker, Georg, et al.. (1978). Zur Bindung von Cyclophosphamid und Cyclophosphamid-Metaboliten an Serum-Albumin. Journal of Cancer Research and Clinical Oncology. 91(2). 127–42. 13 indexed citations
16.
Wagner, Thomas, et al.. (1977). Characterization and quantitative estimation of activated cyclophosphamide in blood and urine.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 37(8 Pt 1). 2592–6. 32 indexed citations
17.
Hj, Hohorst, et al.. (1976). The problem of oncostatic specificity of cyclophosphamide (NSC-26271): Studies on reactions that control the alkylating and cytotoxic activity.. PubMed. 60(4). 309–15. 57 indexed citations
18.
Voelcker, Georg, Theodoro Marcel Wagner, & Hohorst Hj. (1976). Identification and pharmacokinetics of cyclophosphamide (NSC-26271) metabolites in vivo.. PubMed. 60(4). 415–22. 24 indexed citations
19.
Weser, Ulrich & Georg Voelcker. (1972). Evidence for accelerated H2 O2 formation by erythrocuprein. FEBS Letters. 22(1). 15–18. 15 indexed citations
20.
Weser, Ulrich, et al.. (1972). An Enzymic Study on Bovine Erythrocuprein. Hoppe-Seyler´s Zeitschrift für physiologische Chemie. 353(2). 1059–1068. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ulf Niemeyer Breakdown of academic impact, for papers by Jörg Pohl Breakdown of academic impact, for papers by G. Peter Breakdown of academic impact, for papers by Larry M. Allen Breakdown of academic impact, for papers by Yei Mei Peng Breakdown of academic impact, for papers by Eliahu Boger Breakdown of academic impact, for papers by M. J. van Maanen Breakdown of academic impact, for papers by Bo Jiao Breakdown of academic impact, for papers by Shinji Hourai Breakdown of academic impact, for papers by Nicolas Albin
Rankless by CCL
2026